Paragon 28 Inc（FNA）股票分析

$13.090

0.000 (0.00%)收盘时

Loading chart…

High: 13.110
Open: 13.090
VWAP: 13.09
Vol: 19.38M
Mkt Cap: 551.63M
Low: 13.065
Amount: 253.69M
EV/EBITDA, TTM: 238.72

Paragon 28, Inc. is a medical device company. The Company develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products and product families include plates and plating systems, screws, staples, and nails to address all foot and ankle procedures, including fracture fixation, forefoot, or hallux valgus, which includes bunion and hammertoe, ankle, flatfoot, or progressive collapsing foot deformity (PCDF), Charcot foot and Ortho biologics. It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The Company’s suite of surgical solutions comprises 75 product systems, including approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs. Its products are available in a variety of sizes and configurations to suit the individual patient’s anatomical and surgical requirements.

估值指标

The current forward P/E ratio for Paragon 28 Inc (FNA) is -27.89, compared to its 5-year average forward P/E of -39.31.

Forward P/E

Fair

5Y Average P/E

-39.31

Current P/E

-27.89

高估

-17.17

低估

-61.45

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

1.10

Current EV/EBITDA

238.72

高估

714.20

低估

-712.00

Forward P/S

Fair

5Y Average P/S

5.26

Current P/S

3.75

高估

7.45

低估

3.07

事件时间线

2025-03-11 (ET)

16:02:31

Paragon 28 announces expiration of HSR waiting period for pending acquisition

2025-01-28 (ET)

17:02:36

Zimmer Biomet to acquire Paragon 28 for $13.00 per share in cash upfront

2025-01-14 (ET)

11:00:49

Paragon 28 falls -9.5%

2025-01-13 (ET)

07:25:45

Paragon 28 sees Q4 revenue $$71.5M-$71.8M , consensus $69.62M

2024-11-13 (ET)

11:00:53

Paragon 28 rises 36.8%

Show More Events

资讯

FNA FAQ — answered by Alphio AI

Paragon 28, Inc. is a medical device company. The Company develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products and product families include plates and plating systems, screws, staples, and nails to address all foot and ankle procedures, including fracture fixation, forefoot, or hallux valgus, which includes bunion and hammertoe, ankle, flatfoot, or progressive collapsing foot deformity (PCDF), Charcot foot and Ortho biologics. It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The Company’s suite of surgical solutions comprises 75 product systems, including approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs. Its products are available in a variety of sizes and configurations to suit the individual patient’s anatomical and surgical requirements. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。